Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 4
- 主要终点
- Sleep latency during MWT, number of vehicle's line crossing on the road, standard deviation of the vehicle's position on the road
研究概览
简要总结
The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting treatments on driving risks. It will reinforce the links between different research environments (sleep physiopathology, clinical research, cognitive neurosciences, driver's supervision, virtual reality, pharmacology) among the RESAT network (Réseau Eveil Sommeil Attention Transport). It will stimulate data acquisition in technological research to better understand the difference between real and simulated driving
详细描述
Excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck accidents on French Freeways. Since the publication of a new law (arrêté du 28 décembre 2005 du journal officiel) regulating fitness to drive, the Maintenance of Wakefulness Test (MWT) is now mandatory to evaluate driving skills of patients suffering of excessive daytime sleepiness. The MWT has shown a good predictability of driving handicap on simulators in patients suffering from obstructive sleep apnea syndrome. Nevertheless no study has proven yet the predictability of the MWT regarding real and simulated driving in narcoleptics and hypersomniacs. Furthermore, even if alerting drugs significantly improve MWT scores there is no data available concerning the impact of these drugs on fitness to drive. This lack of knowledge is a major handicap to evaluate driving skills of treated patients suffering from excessive daytime sleepiness. The main objective of our project is to test the predictive value of the MWT on real and simulated driving performances in untreated and treated sleepy patients suffering from narcolepsy and hypersomnia. Inclusion of healthy volunteers will allow to collect reference data about somnolence during MWT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •for Patients:
- •Narcoleptic patients with or without cataplexy or hypersomniacs
- •aged from 18 to 65 years,
- •treated for attacks of cataplexy,
- •treated with a maximum dose of Modiodal: 400 mg per day (4 tablets of 100mg),
- •without any other disease which could be responsible of excessive daytime sleepiness,
- •having their driver's licence,
- •driving more than 5000 Km/year,
- •registered to French national health and pensions organization,
- •having regular timetables of life 7 days before beginning the study,
- •having given their written light agreement in order to participate in the study.
- •Inclusion Criteria for Healthy Volunteers:
- •without any sleep disorders,
- •having their driver's licence since at least 2 years,
- •driving more than 5000 Km/year,
- •registered to French national health and pensions organization,
- •having regular timetables of life 7 days before beginning the study,
- •having given their written light agreement in order to participate in the study.
排除标准
- •for Patients:
- •Night workers,
- •breast-feeding or pregnant women
- •Beck's scale score < 8,
- •neurologic disease,
- •cardiovascular disorders including cardiac arrhythmia,
- •sleep disorders except narcolepsy and hypersomnia,
- •pulmonary disorders,
- •renal disorders,
- •endocrinal disorders,
- •having participated in a clinical study during the last 6 months,
- •unable to drive.
- •Exclusion Criteria for Healthy Volunteers:
- •Night workers,
- •neurologic disease,
- •cardiovascular disorders,
- •sleep disorders,
- •pulmonary disorders,
- •renal disorders,
- •endocrinal disorders,
- •having participated in a clinical study during the last 6 months,
- •unable to drive.
研究组 & 干预措施
Modafinil First
Treatment by Modafinil during first condition then placebo during second condition
干预措施: Placebo (Drug)
Placebo First
Treatment by Placebo during first condition then Modafinil during second condition
干预措施: Placebo (Drug)
Modafinil First
Treatment by Modafinil during first condition then placebo during second condition
干预措施: Modafinil (Drug)
Placebo First
Treatment by Placebo during first condition then Modafinil during second condition
干预措施: Modafinil (Drug)
结局指标
主要结局
Sleep latency during MWT, number of vehicle's line crossing on the road, standard deviation of the vehicle's position on the road
时间窗: for each condition, at day 4 for patients or day 1 for healthy volonteers
次要结局
- nocturnal sleep quality and quantity will be measured by PSG and Actimetry.(For each condition, at day 4 and 5 for patients or day 1 for healthy volonteers)
- Subjective sleepiness (Karolinska and VAS scales)(for each condition, at day 4 and 5 for patients or day 1 for healthy volonteers)